To make an appointment with a Valley cancer specialist,
please call 201-634-5339.

Multiple Myeloma

Font ++ Click to Print


Checkmate 602

“An Open-Label, Randomized Phase 3 Trial of Combinations of Nivolumab, Elotuzumab, Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma - CheckMate 602: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 602”

Study Objective: To evaluate the safety and effectiveness of several combination therapies for Multiple Myeloma.

  • Group 1 Experimental: Nivolumab, Pomalidomide and Dexamethasone
  • Group 2 Active Comparator: Control Arm: Pomalidomide and Dexamethasone
  • Group 3 Experimental: Exploratory Arm: Nivolumab, Elotuzumab, Pomalidomide and Dexamethasone

Key Inclusion Criteria:

  • Refractory or relapsed and refractory multiple myeloma
  • Measurable disease
  • Have received ≥ 2 lines of prior therapy which must have included an immune modulatory drug (IMiD) and a proteasome inhibitor alone or in combination
Principal Investigator: Jason Suh, M.D.

Click here for more information on Checkmate 602


Find a Doctor
View all physicians
Contact the Blumenthal Cancer Center

Have a question? Call 201-634-5339 or complete the form below. If you are experiencing a medical emergency, please call your doctor or emergency services provider.

Retype the numbers below:
 Security code